Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G., Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP, «BLOOD», 2009, 113(15), pp. 3428 - 3434 [articolo]
Palandri F; Castagnetti F; Alimena G; Testoni N; Breccia M; Luatti S; Rege-Cambrin G; Stagno F; Specchia G; Martino B; Levato L; Merante S; Liberati AM; Pane F; Saglio G; Alberti D; Martinelli G; Baccarani M; Rosti G., The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up, «HAEMATOLOGICA», 2009, 94(2), pp. 205 - 212 [articolo]
Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G., Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response, «CLINICAL CANCER RESEARCH», 2009, 15, pp. 1059 - 1063 [articolo]
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia, Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up, «HAEMATOLOGICA», 2008, 93(12), pp. 1792 - 1796 [articolo]
Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; GIMEMA Working Party on CML., Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome, «HAEMATOLOGICA», 2008, 93(5), pp. 770 - 774 [articolo]
Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML., Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML., «JOURNAL OF CLINICAL ONCOLOGY», 2008, 26, pp. 106 - 111 [articolo]
Baccarani M.; Castagnetti F.; Iacobucci I.; Palandri F.; Pusiol A., Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables, in: Chronic Myeloproliferative Disorders, OXFORD, Informa healthcare - Taylor & Francis publishers, 2007, pp. 44 - 51 [capitolo di libro]
Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandri F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G., Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party., «HAEMATOLOGICA», 2007, 92, pp. 101 - 105 [articolo]
Palandri F; Iacobucci I; Quarantelli F; Castagnetti F; Cilloni D; Baccarani M; GIMEMA Working Party on CML, Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase, «HAEMATOLOGICA», 2007, 92(11), pp. 1579 - 1580 [articolo]
Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M., Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance, «BIOLOGICS», 2007, 1, pp. 121 - 127 [articolo]Open Access
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain, «HAEMATOLOGICA», 2007, 92, pp. 401 - 404 [articolo]
Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M., Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL, «THE LANCET ONCOLOGY», 2007, 8, pp. 273 - 274 [articolo]
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML), Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia, «CLINICAL CANCER RESEARCH», 2006, 12(24), pp. 7374 - 7379 [articolo]
MARTINELLI G; IACOBUCCI I; ROSTI G; PANE F; AMABILE M; CASTAGNETTI F; CILLONI D; SOVERINI S; TESTONI N; SPECCHIA G; MERANTE S; ZACCARIA A; FRASSONI F; SAGLIO G; BACCARANI M., Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients, «ANNALS OF ONCOLOGY», 2006, 17, pp. 495 - 502 [articolo]
Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M., ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia, «JOURNAL OF CLINICAL ONCOLOGY», 2005, 23, pp. 4100 - 4109 [articolo]
